Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029585 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer
A Phase 2 study, sponsored by NanOlogy.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03029585: Clinical Trial Phase 2 study, sponsored by NanOlogy.
NCT03029585 is a Phase 2 study that was terminated before completion, run by NanOlogy. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029585, a Phase 2 study, was terminated before completion, sponsored by NanOlogy.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.
Primary Outcome
Adverse events will include any clinically relevant changes in laboratory values, vital signs, and physical examination. Treatment-emergent adverse events occur when the date and time of the adverse event onset is on or after the first application of the investigational agent and any time up to when the intravenous chemotherapy commences. Treatment-emergent adverse events will be summarized for each treatment group. The summaries will include an overall summary of the number of subjects reportin
Interventions
- DRUG NanoPac® 100 mg/m2
- DRUG NanoPac® 200 mg/m2
- DRUG NanoPac® 300 mg/m2
- DRUG NanoPac® 400 mg/m2
- DRUG Standard of Care Intravenous Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-04-19 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 2 |
Why NCT03029585 stopped before completion
NCT03029585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which NanoPac® 100 mg/m2 is the first listed.
NCT03029585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03029585 about?
NCT03029585 is a clinical study titled "Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer". This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.
What is the current status of trial NCT03029585?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-04-19. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT03029585?
The interventions under investigation include: NanoPac® 100 mg/m2 (DRUG), NanoPac® 200 mg/m2 (DRUG), NanoPac® 300 mg/m2 (DRUG), NanoPac® 400 mg/m2 (DRUG), Standard of Care Intravenous Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03029585?
This trial is sponsored by NanOlogy, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03029585's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI